| Issue Date | Title | Author(s) |
| 2-Nov-2023 | Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF) | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 2024 | Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yin, Hewen; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 18-Dec-2024 | Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study | Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Wu, Liqing; Yin, Hewen; Lv, Binhua; Xiao, Zhijian; Jin, Jie |
| 5-Nov-2024 | Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial | Zhang, Fengkui; Zhao, Xin; Chang, Hong; Han, Bing; Gao, Sujun; Miao, Miao; Hu, Jianda; Lin, Yanjuan; Liu, Xinjian; Zhang, Lina; Jin, Chenghao; Li, Yingmei; Lin, Shengyun; Jia, Jinsong; Wang, Yi; Chang, Chunkang; Ge, Zheng; He, Guangsheng; Xia, Ruixiang; Fu, Xiangjun; Li, Yuhua; Liu, Hong; Sun, Kai; Wang, Shunqing; Xia, Linghui; Zhang, Weihua; Li, Runzi; Xiong, Junye; Zhai, Wanyi |
| 5-Nov-2024 | Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications | Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Xiao, Zhijian; Jin, Jie |
| Oct-2022 | Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie |
